Track record · closed signal

Danaher Corporation (DHR) — closed signal from July 23, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on October 21, 2025 — +16.5% at the close.

Predicted vs. what happened

DHR price · publication thesis → realized outcomesplit-adjusted
$189.31 Published $222.69 Target $220.46 Window close $234.67 Peak
$183.84 – $190.79Entry zone — fair-value band
$189.31Published — price the day we called it
$222.69Target — the price the thesis aimed for
$234.67Peak — highest point inside the window, not a realized return
$220.46Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 90 days.

At window close
+16.5%
realized, from the publication price to the last close inside the window
Peak gain
+24%
peak, from the publication price — not a realized return
S&P 500, same window
+6.1%
SPY over the identical days, dividend-adjusted
Window close
$220.46
last close inside the window, ended October 21, 2025
Peak price
$234.67
peak on October 21, 2025 — not a realized return
Days to target
90

The thesis — published July 23, 2025

Predicted growth
+18%
over the measurement window
Target price
$222.69
the price the thesis aimed for
Entry zone
$183.84 – $190.79
the fair-value band we waited for
Price at publication
$189.31
published July 23, 2025
Confidence
70%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Danaher says it will earn more per share in 2025 than it first thought, and its biotech arm is already growing 6 percent, yet the stock is still about 25 percent below its old high. The fall appears overdone, with signs that short-term sellers have run out of steam and fresh buyers are stepping in. With plenty of cash to buy smaller firms and a wave of interest in solid health-science companies, the share price could reasonably rebound toward 225 within three months, offering an appealing near-term opportunity.

Primary drivers

  • 2025 profit outlook raised and 6% biotech sales growth tops forecasts.
  • Share price looks exhausted after heavy selling; buyers are returning.
  • $5B cash war chest lets the firm buy smaller companies and grow faster.
  • Money is flowing toward reliable life-science stocks, lifting demand.

How it played out

DHR: target reached in 90 days

Lyra published DHR at 189.31 on 2025-07-23 with an 18% expected gain and a 222.69 target. The thesis pointed to a higher 2025 profit outlook, 6% biotech sales growth, exhausted selling, buyers returning, a $5B cash position for smaller acquisitions, and demand for reliable life-science stocks.

Inside the window, DHR reached a 234.67 peak on 2025-10-21, above the 222.69 target. The target was reached in 90 days. The peak gain was 24%. It ended at 220.46, below the target but still above the publication price. The published thesis played out.

What happened during the window

On October 21, 2025, Danaher reported third-quarter sales of $6.05 billion and adjusted earnings of $1.89 per share, according to Investor's Business Daily.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All DHR signals